On November 18, 2019 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported the pricing of its previously announced public offering of 10,000,000 shares of its common stock, at a public offering price per share of $0.10, for gross proceeds of $1.0 million, before deducting placement agent fees and other offering expenses (Press release, Phio Pharmaceuticals, NOV 18, 2019, View Source [SID1234551409]). The offering is expected to close on or about November 19, 2019, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

Phio intends to use the net proceeds from this offering to fund the development of its immuno-oncology programs, for other research and development activities and for general working capital needs.

The shares of common stock described above were offered by Phio pursuant to a shelf registration statement on Form S-3 (File No. 333-224031) filed with the Securities and Exchange Commission (the "SEC") on March 29, 2018 and declared effective by the SEC on April 6, 2018. A preliminary prospectus supplement and accompanying prospectus related to the offering was filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. When available, electronic copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, via e-mail at [email protected] or via telephone at (646) 975-6996.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On November 18, 2019 TG Therapeutics, Inc. (NASDAQ: TGTX), reported that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference, being held at the Waldorf Hilton on Aldwych, in London, UK (Press release, TG Therapeutics, NOV 18, 2019, View Source [SID1234551425]). The presentation is scheduled to take place on Wednesday, November 20, 2019 at 11:20 AM GMT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source

On November 18, 2019 MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma Industrial) reported the companies have entered into a China-exclusive licensing agreement for SurVaxM, a novel anti-cancer immunotherapy in the treatment of glioblastoma brain cancers (Press release, MimiVax, NOV 18, 2019, https://www.prnewswire.com/news-releases/mimivax-llc-and-shanghai-fosun-pharmaceutical-industrial-development-co-ltd-announce-exclusive-licensing-agreement-on-survaxm-for-glioblastoma-treatment-in-china-300958585.html [SID1234551441]).

Fosun Pharma Industrial is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd (Fosun Pharma), a leading healthcare group in China with extensive healthcare business interests worldwide. It is listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under terms of the agreement, Fosun Pharma Industrial and MimiVax – a clinical-stage biotechnology company in Buffalo, N.Y., USA, developing immunotherapeutics for cancer and autoimmune diseases – will seek to clinically develop and commercialize SurVaxM to make it available for patients in specified territories in China. As part of this agreement MimiVax will receive $10 million USD upfront payment and is eligible to receive additional potential development and sales milestone payments of up to $28 million and $110 million, respectively.

SurVaxM is designed to stimulate the immune system to kill tumor cells that contain survivin, a protein that helps cancer cells resist conventional treatments. SurVaxM triggers T-cell immunity simultaneously with unique antibody-mediated anti-tumor responses.

"MimiVax is committed to disrupting cancer through the development of highly innovative immunotherapeutics aimed at increasing patient survival rates, so we are very excited to be working with Fosun Pharma to bring SurVaxM to China," said Michael J. Ciesielski, Ph.D., MimiVax chief executive officer. "Fosun Pharma has both the expertise and access to reach this fast-growing market."

MimiVax’s proprietary product portfolio is based on technology licensed from Roswell Park Comprehensive Cancer Center that targets survivin. The therapies are designed to stimulate immune responses to control tumor growth and recurrence. The company is now working to initiate a pivotal randomized study of the use of SurVaxM in treating patients with newly diagnosed glioblastoma in 2020 to be performed at cancer centers across the United States and in China.

Fosun Pharma will work with MimiVax on the clinical, regulatory and commercial pathways necessary to bring SurVaxM to China.

"We are pleased to partner with MimiVax to bring such a promising immunotherapy to China," said Yifang Wu, chief executive officer of Fosun Pharma. "The collaboration with MimiVax will enrich Fosun Pharma’s pipeline and provide a potential new therapy addressing clinical unmet needs in the area of neuro-oncology, so we look forward to this new relationship with MimiVax."

On November 18, 2019 Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, reported that the POP1 research and drug discovery program has made significant advancements towards producing synthetic versions of the two proenzymes, trypsinogen and chymotrypsinogen (Press release, Propanc, NOV 18, 2019, View Source [SID1234551410]). With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between lots and without sourcing the proenzymes from animals, the Company is undertaking a challenging research project in collaboration with the universities of Jaén and Granada, led by research scientist Mr. Aitor González, supported by Dr. Macarena Perán, Ph.D. and Dr. Julian Kenyon, M.D. as joint supervisors, representing the Universities and Propanc, respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased with the recent advancements made through our research program, as we are able to produce synthetic recombinant versions of the two proenzymes, trypsinogen and chymotrypsinogen. The two active ingredients are currently naturally derived from animal sources, which combine to form our lead product candidate, PRP. Our vision is to further stabilize and enhance the effects of the proenzymes when administered to patients," said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer.

Mr. James Nathanielsz, Propanc’s Chief Executive Officer said, "As we seek to expand our product pipeline, our vision is to create a new drug product class that provides a solution for the treatment and prevention of recurring and spreading malignant tumors, once perceived as untreatable. Through our PRP development and POP1 drug discovery programs, I am pleased to confirm that we continue to make positive steps towards achieving this vision."

So far, the Company’s scientific researchers have developed a novel expression system. At the research laboratories at the universities of Jaén and Granada, scientific researchers are in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen with this expression system. After western blotting analysis of cell extracts, they observed the cells are producing the proteins, and further sequence analysis will be completed in order to confirm the correct sequence of both proenzymes produced.

One specific objective of the project will be to synthesize by an in vivo system both proenzymes to produce crystalized proteins that could be maintained for long periods without suffering degradation, even in absence of refrigeration. This will be particularly useful for a longer shelf life as well as global distribution of the drug product, particularly in warmer climates and developing regions where refrigeration may not be available.

On November 18, 2019 Varian (NYSE: VAR) reported the South Florida Proton Therapy Institute (SFPTI), a Proton International facility, on the campus of Delray Medical Center, reported that it has treated its first patient utilizing the Varian ProBeam Compact single-room proton therapy system (Press release, Varian Medical Systems, NOV 18, 2019, View Source [SID1234551426]). Proton therapy can be used to treat many types of tumors including in the brain, head and neck, central nervous system and lung, and more precisely targets cancer cells while reducing side effects, minimizing risk to surrounding tissue and organs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Proton therapy is the latest and by far the most advanced radiation treatment available, and at SFPTI we use these highly precise particle beams instead of traditional x-rays to treat tumors more precisely, with much less exposure to the surrounding normal tissues," said Tim Williams medical director, SFPTI. "Proton therapy can be used to treat children with cancer as well as adult tumors of the brain, spine, head and neck, lung, prostate, GI tract, and breast tumors. I am truly grateful to finally be able to make this long-standing vision of bringing this world-class technology to south Florida a reality."

"We are proud of the partnership between Varian, SFPTI and Proton International to help bring this advanced treatment technology to more cancer patients who are in need of this life-saving therapy," said Kolleen Kennedy, president, Proton Solutions and chief growth officer at Varian. "This first patient treatment is another important step in the growing availability of proton therapy for more patients and continues Varian’s mission of creating a world without fear of cancer."

Proton therapy uses protons, accelerated to about two-thirds the speed of light, or more than 100,000 miles per second, to destroy cancer cells, while minimizing exposure to nearby healthy tissues. SFPTI will treat a variety of oncology patients with the Varian system, including brain and spine, head and neck, breast, liver, lung, pancreatic, prostate and pediatric cancers.

Currently 27 leading proton centers have selected the Varian solution, 12 of the centers are in clinical operation and eight more are expected to begin treating patients within the next 12 months. To learn more about the Varian proton therapy solutions, visit View Source

About South Florida Proton Therapy Institute
The South Florida Proton Therapy Institute (SFPTI), a Proton International facility, is a radiation oncology center that opened in 2018 on the campus of Delray Medical Center. Led by Medical Director Tim R. Williams, M.D. and featuring the most innovative technology available, SFPTI provides those in Palm Beach County and the surrounding communities with a tremendous new resource in the fight against cancer. For more information, visit View Source